Baxter International Inc. (BAX) is scheduled to release first-quarter 2025 results on May 1, before the opening bell. In the last reported quarter, the company’s earnings beat the Zacks Consensus Estimate by 11.54%. BAX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 5.92%. (Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.)Q1 EstimatesCurrently, the consensus estimate for revenues is pegged at $2.57 billion, indicating a decline of ...

Baxter International Inc. (BAX) recently introduced Voalte Linq , a lightweight, wearable badge powered by Scotty assistant, a voice-activated technology, at the 2025 HIMSS Global Healthcare Conference. Voalte Linq is the company’s latest innovation within connected care, providing health systems with an ecosystem that promotes full connectivity for care teams and their patients. The latest product introduction by Baxter is aimed at driving workflow automation for hospital settings and transforming how care ...

Research and Development - R&D expenditures were $590 million in 2024, $518 million in 2023, and $450 million in 2022, reflecting a focus on enhancing future growth through clinical differentiation [43]. - The company is working to create a more resilient supply chain and may consolidate R&D facilities as part of its new operating model [43]. Financial Performance and Challenges - The company faced challenges in recovering cost increases for raw materials and components due to contractual limits and market forces, negatively impacting profit margins in 2022 and 2023 [36]. - The company’s profit margins were adversely affected in Q4 2024 due to increased supply chain costs related to ongoing recovery efforts [36]. - The company’s ability to increase prices is constrained by global healthcare cost containment efforts, including price controls and competitive tenders [38]. Workforce and Talent - The company employs approximately 38,000 people globally, with 15,000 in the United States and 23,000 outside the United States, emphasizing the importance of talent in achieving strategic objectives [53]. Regulatory Environment - The company is subject to extensive regulation by government agencies, including the FDA and EMA, impacting the marketing and sale of its products [50]. Competitive Landscape - The company’s competitive advantages include a broad product offering and strong relationships with customers, but it faces substantial competition from both domestic and international healthcare companies [37]. - The company has purchasing agreements with major Group Purchasing Organizations (GPOs) in the U.S., which may limit price increases and create competition from other suppliers [33]. Corporate Governance and Transparency - The company provides free access to its Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K on its website [56]. - Reports are also available via EDGAR through the SEC website, ensuring transparency and accessibility for stakeholders [56]. - Corporate Governance Guidelines and Code of Conduct are accessible on the company's website, promoting accountability and ethical standards [56]. - Stockholders can request printed materials, indicating the company's commitment to shareholder communication [56]. - The company incorporates market risk disclosures in its financial reporting, highlighting its awareness of financial instrument risks [374]. Corporate Responsibility - The company’s corporate responsibility strategy focuses on empowering patients, protecting the planet, and championing communities, with a commitment to report progress annually [48].

FOURTH-QUARTER 2024 EARNINGS Baxter International Inc. February 20, 2025 1 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements concerning the company's financial results (including the outlook for first-quarter and full-year 2025) and business development and regulatory activities. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking ...

Baxter International Inc. (BAX) reported fourth-quarter 2024 adjusted earnings per share (EPS) of 58 cents, which beat the Zacks Consensus Estimate of 52 cents by 11.5%. The bottom line declined 10.8% from the year-ago quarter’s level due to a surge in costs and expenses.On a GAAP basis, the company reported a loss per share of 95 cents against EPS of 43 cents in the prior-year quarter. The significant loss was due to special items, primarily related to the impact of a Front Line Care goodwill impairment ch ...

Baxter International Inc. (NYSE:BAX) Q4 2024 Earnings Conference Call February 20, 2025 8:30 AM ET Company Participants Clare Trachtman - SVP and Chief IRO Brent Shafer - Chairman, and Interim CEO Heather Knight - COO Joel Grade - EVP and CFO Conference Call Participants Robert Marcus - JPMorgan David Roman - Goldman Sachs Matt Miksic - Barclays Vijay Kumar - Evercore ISI Travis Steed - Bank of America Securities Lawrence Biegelsen - Wells Fargo Danielle Antalffy - UBS Operator Good morning, ladies and gent ...

Baxter International (BAX) reported $2.75 billion in revenue for the quarter ended December 2024, representing a year-over-year decline of 29.1%. EPS of $0.58 for the same period compares to $0.88 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $2.66 billion, representing a surprise of +3.49%. The company delivered an EPS surprise of +11.54%, with the consensus EPS estimate being $0.52.While investors scrutinize revenue and earnings changes year-over-year and how they compare wit ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 1, 2025 Baxter International Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) (Commission File Number) 1-4448 36-0781620 (I.R.S. Employer Identification No.) One Baxter Parkway, Deerfield, Illinois 60015 (Address of pri ...

Baxter International Inc. (BAX) is scheduled to release fourth-quarter 2024 results on Feb. 13, before the opening bell. In the last reported quarter, the company’s earnings beat the Zacks Consensus Estimate by 2.56%. BAX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 3.62%.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.Q4 EstimatesCurrently, the consensus estimate for revenues is pegged at $2.66 billion, indicating a decline of 3 ...

In its upcoming report, Baxter International (BAX) is predicted by Wall Street analysts to post quarterly earnings of $0.52 per share, reflecting a decline of 40.9% compared to the same period last year. Revenues are forecasted to be $2.66 billion, representing a year-over-year decrease of 31.5%.Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this ti ...